Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine

Translating academic medical research into new therapies is an important challenge for the biopharmaceutical industry and investment communities, which have historically favored later-stage assets with lower risk and clearer commercial value. The Stanford SPARK program is an innovative model for add...

Full description

Bibliographic Details
Other Authors: Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory (Contributor), Massachusetts Institute of Technology. Department of Chemical Engineering (Contributor), Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science (Contributor), Sloan School of Management (Contributor), Kim, Esther (Contributor), Omura, Paige M. (Contributor), Lo, Andrew W (Contributor)
Format: Article
Language:English
Published: Elsevier BV, 2019-03-05T20:39:23Z.
Subjects:
Online Access:Get fulltext
LEADER 01764 am a22002053u 4500
001 120750
042 |a dc 
245 0 0 |a Accelerating biomedical innovation: a case study of the SPARK program at Stanford University, School of Medicine 
260 |b Elsevier BV,   |c 2019-03-05T20:39:23Z. 
856 |z Get fulltext  |u http://hdl.handle.net/1721.1/120750 
520 |a Translating academic medical research into new therapies is an important challenge for the biopharmaceutical industry and investment communities, which have historically favored later-stage assets with lower risk and clearer commercial value. The Stanford SPARK program is an innovative model for addressing this challenge. The program was created in 2006 to educate students and faculty about bringing academic research from bench to bedside. Every year, the program provides mentorship and funding for approximately a dozen SPARK 'scholars,' with a focus on impacting patient lives, regardless of economic factors. By reviewing the detailed structure, function and operation of SPARK we hope to provide a template for other universities and institutions interested in de-risking and facilitating the translation of biomedical research. 
655 7 |a Article 
100 1 0 |a Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory  |e contributor 
100 1 0 |a Massachusetts Institute of Technology. Department of Chemical Engineering  |e contributor 
100 1 0 |a Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science  |e contributor 
100 1 0 |a Sloan School of Management  |e contributor 
100 1 0 |a Kim, Esther  |e contributor 
100 1 0 |a Omura, Paige M.  |e contributor 
100 1 0 |a Lo, Andrew W  |e contributor 
773 |t Drug Discovery Today